GlassScriptPhysician profile
Ravdeep S Khanuja
NPI 1750433256
$309,987.47
in general payments reported to CMS, 2019-2025
18 companies · $122K in 2025
The $122K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $9,369 · 2021: $45K · 2022: $46K · 2023: $26K · 2024: $23K · 2025: $122K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Consulting Fee: $21K · Travel and Lodging: $15K · Food and Beverage: $7,300 · Education: $7.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128,805.00 |
| Consulting Fee | $20,789.88 |
| Travel and Lodging | $14,531.44 |
| Food and Beverage | $7,299.83 |
| Education | $7.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $164,270.34 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $69,817.11 | 2019-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $38,868.80 | 2024-2025 | Cobenfy |
| Abbvie INC. | $29,408.33 | 2021-2023 | |
| Allergan, INC. | $4,081.42 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $913.13 | 2019-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $581.62 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $531.21 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $517.27 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $487.84 | 2019-2021 | |
| Indivior INC. | $195.90 | 2022-2024 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $92.61 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $75.23 | 2024-2025 | Auvelity |
| Lundbeck LLC | $73.75 | 2020-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $24.77 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $21.03 | 2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $15.08 | 2019 | |
| Eisai INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravdeep Khanuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.